Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative study
Introduction: There is paucity of data on efficacy of isotretinoin versus methotrexate in psoriasis patients. Aims: We compared the efficacy and safety of once a week methotrexate and daily isotretinoin for the treatment of moderateto-severe chronic plaque psoriasis. Methods: 43 (M: F 30:13) conse...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Our Dermatology Online
2015-09-01
|
| Series: | Nasza Dermatologia Online |
| Online Access: | http://www.odermatol.com/odermatology/20154/2.Weekly-AbhinavC.pdf |
| _version_ | 1811232807032193024 |
|---|---|
| author | C. Abhinav Vikram K Mahajan Karaninder S. Mehta Pushpinder S. Chauhan Mrinal Gupta Mrinal Gupta |
| author_facet | C. Abhinav Vikram K Mahajan Karaninder S. Mehta Pushpinder S. Chauhan Mrinal Gupta Mrinal Gupta |
| author_sort | C. Abhinav |
| collection | DOAJ |
| description | Introduction: There is paucity of data on efficacy of isotretinoin versus methotrexate in psoriasis patients. Aims: We
compared the efficacy and safety of once a week methotrexate and daily isotretinoin for the treatment of moderateto-severe
chronic plaque psoriasis. Methods: 43 (M: F 30:13) consenting patients having moderate-to-severe chronic
plaque psoriasis were divided on alternate basis in Group-A for treatment with methotrexate (15mg/week) and Group-B
for isotretinoin (30mg/d) therapy. The clinical response was assessed by the percentage reduction in the baseline
PASI scores during next 12 weeks. Results: 14 patients in Group-A and 11 patients in Group-B completed the study.
The mean percentage reduction in the PASI score was 79.78 ± 20.68 in the methotrexate group and 51.92 ± 23.83
in the isotoin group at the end of 12 weeks. Five patients in Group-A achieved >75% reduction in the PASI score,
while only 3 patients in Group-B showed similar results at the end of 12 weeks signifying faster disease clearance with
methotrexate. Isotretinoin-related serious adverse effects were fewer and did not warrant treatment discontinuation.
Conclusions: Isotretinoin may be an option for alternative therapy in patients who cannot afford acetretin, are intolerant
to methotrexate, have achieved its cumulative dose, or in rotational therapy |
| first_indexed | 2024-04-12T11:10:29Z |
| format | Article |
| id | doaj.art-d01c1b964703464394b43d08b3005977 |
| institution | Directory Open Access Journal |
| issn | 2081-9390 |
| language | English |
| last_indexed | 2024-04-12T11:10:29Z |
| publishDate | 2015-09-01 |
| publisher | Our Dermatology Online |
| record_format | Article |
| series | Nasza Dermatologia Online |
| spelling | doaj.art-d01c1b964703464394b43d08b30059772022-12-22T03:35:38ZengOur Dermatology OnlineNasza Dermatologia Online2081-93902015-09-016439239810.7241/ourd.20154.106Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative studyC. Abhinav0 Vikram K Mahajan1Karaninder S. Mehta2 Pushpinder S. Chauhan3Mrinal Gupta4Mrinal Gupta5Department of Dermatology, Venereology and Leprosy, Dr. R. P. Govt. Medical College, Kangra (Tanda)-176001 (Himachal Pradesh), IndiaDepartment of Dermatology, Venereology and Leprosy, Dr. R. P. Govt. Medical College, Kangra (Tanda)-176001 (Himachal Pradesh), IndiaDepartment of Dermatology, Venereology and Leprosy, Dr. R. P. Govt. Medical College, Kangra (Tanda)-176001 (Himachal Pradesh), IndiaDepartment of Dermatology, Venereology and Leprosy, Dr. R. P. Govt. Medical College, Kangra (Tanda)-176001 (Himachal Pradesh), IndiaDepartment of Dermatology, Venereology and Leprosy, Dr. R. P. Govt. Medical College, Kangra (Tanda)-176001 (Himachal Pradesh), IndiaDepartment of Dermatology, Venereology and Leprosy, Dr. R. P. Govt. Medical College, Kangra (Tanda)-176001 (Himachal Pradesh), IndiaIntroduction: There is paucity of data on efficacy of isotretinoin versus methotrexate in psoriasis patients. Aims: We compared the efficacy and safety of once a week methotrexate and daily isotretinoin for the treatment of moderateto-severe chronic plaque psoriasis. Methods: 43 (M: F 30:13) consenting patients having moderate-to-severe chronic plaque psoriasis were divided on alternate basis in Group-A for treatment with methotrexate (15mg/week) and Group-B for isotretinoin (30mg/d) therapy. The clinical response was assessed by the percentage reduction in the baseline PASI scores during next 12 weeks. Results: 14 patients in Group-A and 11 patients in Group-B completed the study. The mean percentage reduction in the PASI score was 79.78 ± 20.68 in the methotrexate group and 51.92 ± 23.83 in the isotoin group at the end of 12 weeks. Five patients in Group-A achieved >75% reduction in the PASI score, while only 3 patients in Group-B showed similar results at the end of 12 weeks signifying faster disease clearance with methotrexate. Isotretinoin-related serious adverse effects were fewer and did not warrant treatment discontinuation. Conclusions: Isotretinoin may be an option for alternative therapy in patients who cannot afford acetretin, are intolerant to methotrexate, have achieved its cumulative dose, or in rotational therapyhttp://www.odermatol.com/odermatology/20154/2.Weekly-AbhinavC.pdf |
| spellingShingle | C. Abhinav Vikram K Mahajan Karaninder S. Mehta Pushpinder S. Chauhan Mrinal Gupta Mrinal Gupta Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative study Nasza Dermatologia Online |
| title | Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative study |
| title_full | Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative study |
| title_fullStr | Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative study |
| title_full_unstemmed | Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative study |
| title_short | Weekly methotrexate versus daily isotretinoin to treat moderate-to-severe chronic plaque psoriasis: a comparative study |
| title_sort | weekly methotrexate versus daily isotretinoin to treat moderate to severe chronic plaque psoriasis a comparative study |
| url | http://www.odermatol.com/odermatology/20154/2.Weekly-AbhinavC.pdf |
| work_keys_str_mv | AT cabhinav weeklymethotrexateversusdailyisotretinointotreatmoderatetoseverechronicplaquepsoriasisacomparativestudy AT vikramkmahajan weeklymethotrexateversusdailyisotretinointotreatmoderatetoseverechronicplaquepsoriasisacomparativestudy AT karanindersmehta weeklymethotrexateversusdailyisotretinointotreatmoderatetoseverechronicplaquepsoriasisacomparativestudy AT pushpinderschauhan weeklymethotrexateversusdailyisotretinointotreatmoderatetoseverechronicplaquepsoriasisacomparativestudy AT mrinalgupta weeklymethotrexateversusdailyisotretinointotreatmoderatetoseverechronicplaquepsoriasisacomparativestudy AT mrinalgupta weeklymethotrexateversusdailyisotretinointotreatmoderatetoseverechronicplaquepsoriasisacomparativestudy |